全文获取类型
收费全文 | 126488篇 |
免费 | 6371篇 |
国内免费 | 2180篇 |
专业分类
耳鼻咽喉 | 1262篇 |
儿科学 | 1770篇 |
妇产科学 | 1350篇 |
基础医学 | 11865篇 |
口腔科学 | 5136篇 |
临床医学 | 10843篇 |
内科学 | 18720篇 |
皮肤病学 | 1849篇 |
神经病学 | 8203篇 |
特种医学 | 3431篇 |
外国民族医学 | 12篇 |
外科学 | 20186篇 |
综合类 | 14659篇 |
现状与发展 | 2篇 |
一般理论 | 12篇 |
预防医学 | 10873篇 |
眼科学 | 2040篇 |
药学 | 8677篇 |
141篇 | |
中国医学 | 9671篇 |
肿瘤学 | 4337篇 |
出版年
2023年 | 1744篇 |
2022年 | 3027篇 |
2021年 | 4645篇 |
2020年 | 3664篇 |
2019年 | 7536篇 |
2018年 | 7516篇 |
2017年 | 5373篇 |
2016年 | 2908篇 |
2015年 | 2687篇 |
2014年 | 5715篇 |
2013年 | 5435篇 |
2012年 | 4716篇 |
2011年 | 5766篇 |
2010年 | 5045篇 |
2009年 | 4025篇 |
2008年 | 3771篇 |
2007年 | 3957篇 |
2006年 | 3674篇 |
2005年 | 3044篇 |
2004年 | 2526篇 |
2003年 | 2279篇 |
2002年 | 1677篇 |
2001年 | 1588篇 |
2000年 | 1319篇 |
1999年 | 1195篇 |
1998年 | 878篇 |
1997年 | 842篇 |
1996年 | 688篇 |
1995年 | 729篇 |
1994年 | 655篇 |
1993年 | 509篇 |
1992年 | 494篇 |
1991年 | 436篇 |
1990年 | 345篇 |
1989年 | 365篇 |
1988年 | 354篇 |
1987年 | 309篇 |
1985年 | 3219篇 |
1984年 | 3713篇 |
1983年 | 3134篇 |
1982年 | 3600篇 |
1981年 | 3285篇 |
1980年 | 2764篇 |
1979年 | 2728篇 |
1978年 | 2259篇 |
1977年 | 1715篇 |
1976年 | 2128篇 |
1975年 | 1585篇 |
1974年 | 1400篇 |
1973年 | 1323篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
《The British journal of oral & maxillofacial surgery》2022,60(7):890-895
Patients undergoing sentinel node biopsy (SLNB) for early oral squamous cell carcinoma (OSCC) who harbour occult metastases (pN+ve) may be at greater risk of mortality due to prolonged overall treatment times than those identified as pN+ve on elective neck dissection (ELND). A retrospective comparative survival analysis was therefore undertaken to test this hypothesis. Patients were identified from the South Glasgow multidisciplinary team (MDT) database. Group 1 comprised 38 patients identified as pN+ve, or who were false negative, on sentinel lymph node biopsy (SLNB). Group 2 comprised 146 patients staged pN+ve on ELND. The groups were compared with the Kaplan Meier method and Cox proportional hazards model. In addition, a matched-pair analysis was performed. A unique and specifically designed algorithm was deployed to optimise the pairings. No difference in disease-specific or overall survival was found between the groups. Patients undergoing SLNB as the initial neck staging modality in early OSCC and are identified as pN+ve do not appear to be at a survival disadvantage compared with those staged with ELND. 相似文献
5.
6.
7.
8.
ObjectivesMap regional lymph node metastases for lateralized oral cavity squamous cell carcinoma (OCSCC) and evaluate factors associated with regional metastases and recurrence.Materials and methodsRetrospective cohort study of 715 patients with lateralized OCSCC surgically treated in 1997–2011. Analysis was performed using log-rank, Kaplan-Meier, and multivariable logistic and Cox regression.ResultsRegional metastases were identified in ipsilateral levels IIA (24%), IB (18%), III (13%), V (9%), IV (7%), IA (2%) and IIB (1%) and the contralateral neck (3%). Lymphovascular invasion (LVI) (Hazard Ratio [HR] 2.2, 95% Confidence Interval [CI] 1.2–3.9) and T category (T3 vs. T1: HR 4.1, 95% CI 1.9–9.3; T4 vs. T1: HR 2.3, 95% CI 1.2–4.3) were associated with regional metastases. Most (71%) isolated regional metastatic recurrences were in undissected levels of the neck, including 58% in levels IV and V. Tumors of the hard palate (HR 4.3, 95% CI 1.2–16.1), upper alveolus (HR 3.2, 95% CI 1.0–4.7) or with LVI (HR 2.0, 95% CI 1.0–3.9) were associated with isolated regional recurrence. For upper alveolar/hard palate tumors, depth of invasion (DOI) ≥4 mm (P = .003) and LVI (P = .04) were associated with regional metastases.ConclusionsFor lateralized OCSCC, elective neck dissection of level IIB or the contralateral neck may rarely be needed, but additional surgical or radiation treatment of levels IV and V may be considered based on patient risk factors, including T category 3–4 or LVI. For upper alveolar/hard palate tumors, DOI ≥4 mm is an appropriate threshold for elective neck dissection. 相似文献
9.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):359-367.e8
PurposeTo review and to compare indirectly the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Materials and MethodsA literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostatic artery embolization (PAE). Data on the following variables were included: International prostate symptom score (IPSS), maximum urinary flow rate, quality of life, and postvoid residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect.ResultsThere was no significant difference in outcomes between therapies for IPSS at the 3, 6, and 12-month follow ups. Although outcomes for Rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation versus PAE versus Rezum. TURP PVR was significantly better than Urolift at 3, 6, and 12 months. No significant differences in minor or major adverse events were noted.ConclusionAlthough significant differences in outcomes were limited, Aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while Aquablation has limited high quality data and has been associated with bleeding-related complications. 相似文献
10.